Study Name:
Liberty N.O.T.U.S.
Targeted Disease(s):
COPD
Purpose of Study:
To evaluate the safety and efficacy of dupliumab in patients with moderate to severe COPD.
Study Dates:
June 1, 2020 - July 1, 2023
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Industry
Sponsors:
Sanofi
ClinicalTrails.gov Identifier:
NCT04456673
Sponsor:
Sanofi
Trial URL:
COPDClinicalStudies.com
